CIP2A is over‐expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Introduction: CIP2A is a newly identified inhibitor of PP2A. It can stabilize c‐Myc and promote anchorage‐independent cell growth and tumour formation. CIP2A is over‐expressed in some solid tumours although its expression in acute myeloid leukaemia (AML) is still unknown. Methods: CIP2A mRNA and protein expressions were determined in bone marrow mononuclear cells of both patients with AML and healthy controls using reverse transcription polymerase chain reaction and Western blot, respectively. We used siRNA to knock‐down CIP2A expression in HL60 cells and then examined its potential roles during the pathological progression of AML. Results: CIP2A mRNA was present in 54 of 70 (77.14%) patients with newly diagnosed AML and in 11 of 14 (70.86%) patients with relapsed AML, which was significantly higher than complete remission specimens and healthy controls (P < 0.001). Knock‐down of CIP2A in HL60 cells slowed down cell proliferation, decreased clonogenic activity and promoted cell differentiation. Conclusion: These results suggest that CIP2A is over‐expressed in patients with newly diagnosed/relapsed AML and the expression of CIP2A could have potential use as a clinical marker for AML relapse after treatment. The high expression of CIP2A in HL60 cells may be related to active cell proliferation and arrest of cell differentiation. This study may shed light on the molecular function of CIP2A in myeloid leukemogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426
Hoo, L. S., Zhang, J. Y., & Chan, E. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205625 · Cited by 201
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 1×
“…remission (CR) with traditional chemotherapy, newly developed molecular target therapy or bone marrow transplantation, relapse and drug resistance are still common and the long-term survival is poor for most cases (Lapidot et al., 1994; Hudson et al., 1997; Mertens et al., 2001; Pui et al., 2003).”
Background
Cited by
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
“It has been shown that CIP2A deletion results in a reduction of oncogenic potential for multiple tumors (20, 26, 32).”
BackgroundKhanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
“several different human cancer cell types (4, 6, 7).”
BackgroundLucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122
“In contrast, CIP2A has emerged as a novel oncoprotein and a growing number of reports have shown its overexpression in many human malignancies, including breast cancers [21,24,26-31].”
Metadata
- Authors
- WANG, J., LI, W., LI, L., YU, X., JIA, J., & CHEN, C.
- Venue
- International Journal of Laboratory Hematology
- Publisher
- Wiley
- Published
- 2011-01-11
- Volume
- 33
- Issue
- 3
- Pages
- 290-298
- ISSN
- 1751-5521 (ISSN-L)
- 1751-553X
- OpenAlex
- W1809486093
- Cited by
- 67
- References
- 5
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CIP2A is over‐expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. https://app.cochat.ai/papers/10.1111/j.1751-553x.2010.01288.x
- The paper
- WANG, J., LI, W., LI, L., YU, X., JIA, J., & CHEN, C. (2011). CIP2A is over‐expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International Journal of Laboratory Hematology. https://doi.org/10.1111/j.1751-553x.2010.01288.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.